Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003124 · ClinicalTrials.gov registry record · Phase 2
Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer
A Phase 2 study, sponsored by Herbert Irving Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT00003124 is a Phase 2 study that has completed, run by Herbert Irving Comprehensive Cancer Center. The registered enrollment target is 105 participants.
The verdict
NCT00003124, a Phase 2 study, has completed, sponsored by Herbert Irving Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of androgens. Combining radiation therapy with hormone therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of hormone therapy plus radiation therapy in treating patients with prostate cancer.
Interventions
- DRUG leuprolide acetate
- RADIATION radiation therapy
- DRUG flutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 1997-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003124
The ClinicalTrials.gov registry entry for NCT00003124 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Herbert Irving Comprehensive Cancer Center, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which leuprolide acetate is the first listed.
NCT00003124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003124 about?
NCT00003124 is a clinical study titled "Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer". RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of androgens. Combining radiation therapy with hormone therapy may kill more tumor cells. PURPOSE: Phase II trial to study the ...
What is the current status of trial NCT00003124?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 1997-05. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00003124?
The interventions under investigation include: leuprolide acetate (DRUG), radiation therapy (RADIATION), flutamide (DRUG).
Who is sponsoring clinical trial NCT00003124?
This trial is sponsored by Herbert Irving Comprehensive Cancer Center, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.